250PEGFR TESTING FROM CIRCULATING CELL-FREE DNA: READY FOR ROUTINE PRACTICE

Aim: Detection of EGFR alterations is critical for predicting the response to tyrosine kinase inhibitors (TKI) in patients with non-small-cell lung cancer (NSCLC). In clinical practice, somatic mutations are detected using formalin-fixed, paraffin-embedded tumor tissues obtained at diagnosis. However, using archival tumor material for mutation testing can be limited by inherent problems, such as insufficient tumor material, low percentage of tumor cells, DNA degradation, and long turnaround time because tracing archival tumor material can be logistically difficult. The aim of our work was to set up and evaluate a routine procedure enabling to detect EGFR alterations in plasma DNA of patients with NSCLC.